Epigenetic Driver of Glioblastoma Provides New Therapeutic Target|
Researchers report that an enzyme known as lysine-specific demethylase 1 turns off genes required to maintain cancer stem cell properties in glioblastoma, a highly aggressive form of brain cancer. This epigenetic activity helps explain how glioblastoma can resist treatment. [Press release from University of California, San Diego discussing online prepublication in Proceedings of the National Academy of Sciences USA]
Cancer Stem Cells: A Challenging Paradigm for Designing Targeted Drug Therapies|
The authors examine the feasibility of leveraging current know-how of the molecular biology of cancer stem cells and their cellular milieu to design futuristic, targeted drugs with potentially lower toxicity that can override the multiple drug-resistance issues currently observed with existing therapeutics. [Drug Discov Today] Abstract
Emerging Role of CD44 in Cancer Stem Cells: A Promising Biomarker and Therapeutic Target
The authors summarize the current findings concerning the critical role of CD44/CD44v in the regulation of cancer stemness and the research status of CD44/CD44v as biomarkers and therapeutic targets in cancer. They also discuss the current challenges and future directions that may lead to the best use of CD44/CD44v for clinical applications. [Stem Cells Transl Med] Abstract
Visit our reviews page to see a complete list of reviews in the cancer stem cell research field.
UC San Diego and GSK Collaborate to Eradicate Cancer Stem Cells, Treat Leukemia|
Researchers at the University of California (UC), San Diego School of Medicine and Moores Cancer Center are working with GSK on a bench-to-bedside project to treat leukemia and other diseases by eliminating cancer stem cells. [UC San Diego] Press Release
Sorrento and NantBioScience Form Joint Venture to Develop Moonshot Program Targeted Small Molecule Therapies against Cancer
Sorrento Therapeutics, Inc. and NantBioScience, Inc. announced that they have established a joint venture to focus on the development of ‘first-in-class’ small molecules against targets that have eluded the pharmaceutical industry to date and which may address important drivers of cancer growth including cancer stem cells. [Sorrento Therapeutics, Inc]
Ludwig Cancer Research and University of Oxford Launch Cancer Immunotherapy Spinout
Isis Innovation, the University of Oxford’s technology commercialization company, and Ludwig Cancer Research announced the launch of a new spinout company, iOx Therapeutics. iOx Therapeutics will develop a novel cancer immunotherapy discovered through a collaboration between Ludwig Cancer Research and Professor Vincenzo Cerundolo, the director of the MRC Human Immunology Unit within the University of Oxford’s Weatherall Institute of Molecular Medicine. [Ludwig Cancer Research]
Cancer Research UK and Cancer Research Technology Announce Partnership with Monopar Therapeutics to Develop New Oncology Compound
Cancer Research UK and Cancer Research Technology have reached agreement with Monopar Therapeutics LLC to take forward Monopar’s experimental antibody treatment HuATN-658 into clinical trials in cancer patients with advanced solid tumors. [Cancer Research UK ] Press Release
FDA Grants Fast Track Designation to Tocagen’s Toca 511 & Toca FC for Treatment of Recurrent High Grade Glioma
Tocagen Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its lead immuno-oncology product, Toca 511 & Toca FC, for the treatment of recurrent high grade glioma, which includes glioblastoma and anaplastic astrocytoma. [Tocagen Inc. ] Press Release
Georgetown Lombardi Comprehensive Cancer Center and John Theurer Cancer Center Launch Transformational Collaboration to Advance Cancer Research
Georgetown Lombardi Comprehensive Cancer Center and John Theurer Cancer Center, part of Hackensack University Medical Center, announced that they have developed a joint cancer research agenda as part of a multi-year plan to form a National Cancer Institute recognized cancer consortium. [Georgetown Lombardi Comprehensive Cancer Center (PR Newswire Association LLC)]
From our sponsor: Learn how to form and isolate neural rosettes more efficiently.
Watch the video.